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We developed a 65 type 2 diabetes (T2D) variant–weighted
gene score to examine the impact on T2D risk assessment
in a U.K.-based consortium of prospective studies, with
subjects initially free from T2D (N = 13,294; 37.3% women;
mean age 58.5 [38–99] years). We compared the perfor-
mance of the gene score with the phenotypically derived
Framingham Offspring Study T2D risk model and then the
two in combination. Over the median 10 years of follow-
up, 804 participants developed T2D. The odds ratio for
T2D (top vs. bottom quintiles of gene score) was 2.70
(95% CI 2.12–3.43). With a 10% false-positive rate, the
genetic score alone detected 19.9% incident cases,
the Framingham risk model 30.7%, and together 37.3%.
The respective area under the receiver operator charac-
teristic curves were 0.60 (95% CI 0.58–0.62), 0.75 (95% CI
0.73 to 0.77), and 0.76 (95% CI 0.75 to 0.78). The combined
risk score net reclassiﬁcation improvement (NRI) was
8.1% (5.0 to 11.2; P = 3.313 1027). While BMI stratiﬁcation
into tertiles inﬂuenced the NRI (BMI £24.5 kg/m2, 27.6%
[95% CI 17.7–37.5], P = 4.82 3 1028; 24.5–27.5 kg/m2,
11.6% [95% CI 5.8–17.4], P = 9.88 3 1025; >27.5 kg/m2,
2.6% [95% CI 21.4 to 6.6], P = 0.20), age categories did
not. The addition of the gene score to a phenotypic risk
model leads to a potentially clinically important improve-
ment in discrimination of incident T2D.
Type 2 diabetes (T2D) is an important and increasingly
prevalent condition with a high morbidity, resulting in
a growing cost to health services. Notably, individuals
frequently remain asymptomatic until presenting with
complications. Age and obesity are the major environ-
mental risk factors for T2D; the latter is driven by the
increased intake of processed food and sedentary behav-
iors, with commensurate raised calorie intake, inﬂuenced
by a Western-style diet, and is becoming more prevalent
in low- and middle-income countries. However, a subset
of T2D patients remain lean and are likely to represent a
different subtype of the disease with less macrovascular dis-
ease, who, with an extended life span, develop microvascular
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complications (1,2). For these reasons, there is interest in
developing tools for the prediction of T2D, with one sys-
tematic review identifying 84 different risk algorithms
with the area under the receiver operating characteristic
curves (AROCs) ranging from 0.62 to 0.90 (3). It was noted
that several of these had not been externally validated and
no one algorithm performed best (3).
The expectation, in the early phase of the genome-wide
association studies (GWAS), was that this approach would
lead to the identiﬁcation of novel genetic risk loci to aid in
risk prediction of complex diseases such as T2D. However,
the overall variance in disease risk explained by the
identiﬁed loci remained low, and there is a pervading
negativity about the use of genetic information in risk
prediction and clinical utility (4).
In 2010, we compared the performance of a genetic risk
score based on 20 known T2D risk alleles in combination
with the phenotypic-derived Framingham Offspring T2D
risk score (FORS) (5) in the prospective Whitehall II study
(WHII) of U.K. civil servants (6). The results were not
encouraging; a genetic risk score weighted by the effect
size of each of the 20 single nucleotide polymorphisms
(SNPs) did not improve discrimination, risk estimation,
or reclassiﬁcation of individuals who went on to develop
T2D compared with the FORS alone. A recent review of 19
studies, reported prior to 2013, which used between 2 and
40 risk alleles, providing AROCs ranging from 0.54 to 0.63,
concluded that genetic variants did not improve prediction
over established phenotypic predictors.
GWAS since 2012 have identiﬁed additional T2D suscep-
tibility loci, and meta-analysis of studies using gene-centric
chips (7,8) has brought the total number of known T2D risk
variants close to 70. Since these in combination explain more
of the variation in T2D risk, using the increased number of
risk alleles may also improve risk prediction.
The ﬁrst study to use the expanded risk SNPs examined
whether 40 T2D risk SNPs in a weighted risk score could
improve the C-statistic, when added to a phenotypic risk
score, on incident T2D in 3,471 individuals, of whom 446
developed T2D over 34-year follow-up. Using age stratiﬁ-
cation above or below 50 years, there was no improvement
to the C-statistic, but there was a signiﬁcant increase in the
net reclassiﬁcation improvement (NRI) in those below 50
years but not in those 50 years old or above (9). Walford
et al. (10) went on to use a 62 SNP–weighted gene score
(206 incident T2D cases in a total of 1,622 individuals
followed for 13.4 years). This larger genetic risk score did
provide improvement to the C-statistic of the combined
genetic and phenotypic risk scores over either risk score
alone, suggesting complementation for metabolic and ge-
netic information. A second study examined the efﬁcacy of
a 62-SNP gene score in T2D prediction in the Framingham
Offspring Study (3,869 subjects, of whom 446 developed
T2D) and the multiethnic Coronary Artery Risk Develop-
ment in Young Adults (CARDIA) study (total of 1,650
whites with 97 incident T2D cases, and among the 820
blacks, 118 developed T2D). While the gene score was
associated with incident T2D risk and an improved C-
statistic when combined with phenotypic risk factors, there
was no improvement in net reclassiﬁcation (11). There was
also no evidence of an interaction between the genetic risk
score and obesity in the determination of T2D susceptibil-
ity (11). The much larger EPIC InterAct case-control cohort
with .12,000 T2D cases and .16,000 controls reported
that a 49-SNP T2D genetic risk score had a greater effect
on the development of T2D in younger and leaner individ-
uals (12), but the investigators did not examine the effect
of other parameters of risk assessment.
Our aim was to determine whether using the expanded
number of 65 T2D genetic variants improves risk pre-
diction and also to explore whether risk prediction,
including a genetic risk score, differs by age and BMI.
Since heritability for T2D decreases with increasing age
(13), we might anticipate that genetic variants would im-
prove prediction in younger individuals. Moreover, addi-
tion of genetic variants to T2D risk might vary by BMI
depending on whether the prediction tool is enriched for
adiposity-related SNPs. We incorporated seven prospec-
tive cohort studies with over 13,000 individuals initially
free of T2D, 804 of whom developed incident T2D during
follow-up, thus providing information on discrimination,
risk estimation, and net reclassiﬁcation in the largest
study to date. These studies were part of the University
College London-London School of Hygiene and Tropical
Medicine-Edinburgh-Bristol (UCLEB) Consortium.
RESEARCH DESIGN AND METHODS
UCLEB Consortium
A full description of the UCLEB Consortium has been
previously published (14). For the current analysis, seven
cohorts with genotype and complete incident T2D informa-
tion were included, comprising a total of 13,294 individuals,
of whom 804 developed T2D over the period of study.
Brieﬂy, the 12 UCLEB studies are almost exclusively
of European ancestry and cover a wide geographic range
within the U.K. Population structure was assessed by
principal components analysis, and outliers were excluded.
All studies have longitudinal follow-up ranging from 5 to
62 years (for a full description, see the Supplementary
Data). MetaboChip genotype information was available
on 21,474 individuals. For the current analysis, the follow-
ing cohorts with genotype and complete incident T2D in-
formation were included: British Regional Heart Study
(BRHS; N = 2,317), British Women’s Heart and Health
Study (BWHHS; N = 1,854), Edinburgh Artery Study
(EAS; N = 703), Medical Research Council National Survey
of Health and Development (MRC NSHD; N = 2,410),
WHII (N = 3,045), English Longitudinal Study of Aging
(ELSA; N = 1,685), and Caerphilly Prospective Study
(CAPS; N = 1,280). A total of 13,294 individuals were
included. The 1,542 individuals with prevalent T2D were
excluded from the analysis, and over the period of study,
804 developed T2D (for full details of individual studies see
the Supplementary Data).
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Clinical Characteristics of the Participants
All studies have harmonized information on a wide range
of risk factor and disease variables in a shared data set, as
previously described (14). For the current analysis, data
on blood lipids, fasting glucose, age, sex, blood pressure,
and BMI were used, as well as data on incident diabetes;
additional data on family history of T2D were requested
from individual cohorts. Medication data were also collated,
including lipid-lowering drugs (statins or other medication),
blood pressure–lowering drugs, and glucose-lowering
drugs. Classiﬁcation as “prevalent T2D” was based
on self-report, medical record review, use of glucose-
lowering medication, and/or a fasting glucose.7 mmol/L.
Within individual cohorts, biochemical measurements
were performed in accredited laboratories using interna-
tional standards. DNA was extracted from blood samples
either collected at baseline (BWHHS) or at a subsequent
resurvey (BRHS, MRC NSHD, EAS, WHII, ELSA, and
CAPS).
Deﬁnition of T2D
An individual was coded as developing T2D if the
condition was self-reported or recorded by medical record
review, if a new prescription of a glucose-lowering
medication was recorded, or following a recorded fasting
glucose of 7 mmol/L or higher (nonfasting in the case of
BRHS). For MRC NSHD, glucose levels were estimated
based on fasting HbA1c levels (15).
Genotyping
Genotypes of 13,294 individuals for T2D susceptibility
variants were obtained using MetaboChip, an array that
includes almost 200,000 SNPs, which cover the loci
identiﬁed by GWAS in cardiometabolic diseases, including
rare variants identiﬁed by the 1000 Genomes Project (16).
Duplicate samples were genotyped to compute the error
rate. Quality control analysis on genotyped samples has
been previously reported (14), and all included SNPs had
a call rate of.98%. All genotypes were in Hardy-Weinberg
Equilibrium in all studies.
We used the list of T2D risk SNPs recently identiﬁed in
a large meta-analysis (8). The SNP, the nearest gene with
chromosome number, the minor allele frequency, and the
reported effect size are presented in Supplementary Table 1.
For each gene, the lead SNP reported by Morris et al. (8)
was chosen. Genotype data were available on all 65 iden-
tiﬁed T2D SNPs, including the adiposity genes FTO and
MC4R, both previously associated with T2D.
Statistical Analysis
Score Construction
We used the published regression coefﬁcients for age,
sex, parental history of T2D, BMI, blood pressure, HDL
cholesterol, triglyceride, and fasting glucose level to
compute the FORS (5). We computed a genetic risk score
using the published coefﬁcients (log odds ratios [ORs]) for
65 SNPs identiﬁed by prior GWAS meta-analysis and pre-
viously reviewed (8,17). Coefﬁcients were multiplied by 0,
1, or 2 according to the number of risk alleles carried by
each person, and the score was centered by subtracting
the mean. The two scores were added to produce a com-
bined score. In addition to the weighted genetic risk score,
we also calculated an unweighted score by summing the
number of risk alleles.
Association Testing
Associations of individual SNPs with risk markers were
assessed by regression, and a signiﬁcance level of P ,
0.001 was used after Bonferroni correction for the num-
ber of SNPs analyzed. Logistic regression models were
ﬁtted to obtain the OR per SD increase in the gene score
as well as OR associated with each quintile. Association
models were ﬁtted using the combined data set with
a term for study included in the model.
Model Discrimination
We calculated the AROC and the detection rate, deﬁned as
the proportion of all cases detected for a false-positive
rate (FPR) of 5 and 10%. AROCs were calculated separately
for each study and combined using ﬁxed effects meta-
analysis. Improvements in the receiver operating charac-
teristic area were assessed by calculating the difference
between the two receiver operating characteristic areas
in each study along with bootstrap estimates of the CI
and then combining these over all the studies.
Model Calibration
Estimates of risk were obtained by converting the logit
given by the weighted coefﬁcients back to a probability.
Observed and estimated risks were converted to 10-year
risk, taking the length of follow-up into account. Observed
risks were then compared with predicted risks and the
Hosmer-Lemeshow test was used to assess goodness of ﬁt.
Reclassiﬁcation of T2D Risk
We used the NRI that quantiﬁes the extent to which the
combined score moved people to risk categories that better
reﬂected their event status (18). As three of the studies
were of case-control design, we used a weighted version of
the NRI, weighting controls by the inverse of the sampling
probability and assigning a weight of 1 to cases (19). We
used four 10-year T2D risk categories (#5, 5–9.9, 10–14.9,
and 15% or higher). We also calculated both the continuous
NRI, which does not require categories, as changes are de-
ﬁned by any upward or downward change in predicted
risks, and the integrated discrimination improvement
(IDI) as recommended (18). Analyses were conducted for
the entire cohort and then within subgroups stratiﬁed by
tertiles of age and BMI (,24.5, 24.5–27.5, .27.5 kg/m2)
and in men and women separately.
All analysis was conducted using Stata version 13.1
(StataCorp, TX).
RESULTS
The baseline characteristics and T2D incident rates of the
subjects in the individual studies are presented in Table 1.
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Of the 13,294 subjects (range of follow-up 4–20 years,
median 10 years), 804 (6.1%) developed T2D, but the
incidence rate differed among studies, in keeping with
variation in mean age and duration of follow-up.
Association and Discrimination Based on the FORS
The OR comparing the top and bottom quintiles of the
FORS distribution was 21.07 (95% CI 14.86–29.88), and
the OR for a 1 SD increase of the FORS score was 2.70
(95% CI 2.48–2.93; P = 5.4 3 102121) (Table 2). The ORs
for the individual studies are presented in Supplementary
Table 2. The AROC for the entire data set was 0.75 (95% CI
0.74–0.77) (Table 3 and, for the individual studies, Sup-
plementary Fig. 1 and Supplementary Table 3). With
a 10% FPR, the Framingham risk model alone identiﬁed
30.7% of cases. The corresponding detection rate for a 5%
FPR was 18.6%. There was signiﬁcant heterogeneity be-
tween detection rates for the seven studies (Fig. 1A). The
Forest plot for a 5% FPR for the seven studies is pre-
sented in Supplementary Fig. 2A. There was no difference
when a random-effects model was used (data not shown).
Association and Discrimination Using Genotype-Based
Risk Scores
The point estimates for 53 of the 65 SNPs used in this
study were consistent with those reported in prior meta-
analyses involving many thousands of T2D cases (Sup-
plementary Table 1). After correction for multiple testing,
eight of the variants contributing to the T2D genetic risk
score were also associated with nongenetic variables in-
cluded in the FORS algorithm, including BMI and fasting
glucose (Supplementary Table 3A–E).
The distribution of a gene score based on these
variants, weighted by the published effect sizes, in
participants initially T2D free is shown in Fig. 2. For
the unweighted score, see Supplementary Fig. 3. The OR
for T2D among individuals in the top versus the bottom
quintile of the gene score distribution for the weighted gene
score was 2.70 (95% CI 2.12–3.43; P = 7.03 3 10216).
Thirty-one percent of incident T2D individuals were in the
top quintile of the weighted gene score compared with
19.3% of T2D-free individuals, and the OR for a 1 SD in-
crease was 1.43 (95% CI 1.33–1.54; P = 2.25 3 10222). The
ORs for the individual studies are presented in Supplemen-
tary Table 2 and the AROCs in Supplementary Table 4. With
a 10% FPR, the genetic score alone detected 19.9% of in-
cident cases. The corresponding value for a 5% FPR was
11.8%. The AROC was 0.60 (95% CI 0.58–0.62).
Effect of Adding Genetic Information to Discrimination
Based on the FORS
The OR for the top versus the bottom quintile of the
combined FORS and weighted gene score was 22.60 (95%
CI 15.80–32.40). The addition of genetic information to
the FORS marginally improved discrimination as assessed
by the increase in the AROC from 0.75 to 0.76 (difference
0.012 [95% CI 0.006–0.018]; P = 0.0003) (Fig. 3 and Table
4). The disease detection rate for a 5% FPR was increased
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from 18.6% (95% CI 15.9–21.2) to 23.1% (95% CI 20.2–
26.1), and for a 10% FPR, the improvement was even
greater from 30.7% (95% CI 27.5–33.8) to 37.3% (95% CI
33.9–40.6) (Table 4 and Supplementary Table 5). Forest
plots of the seven studies for these two FPRs are presented
in Fig. 1B and Supplementary Fig. 2B, respectively.
Calibration of the Phenotype-Only and Combined Risk
Models
Individuals were assigned into four 10-year T2D risk
categories (#5, 5–9.9, 10–14.9, and 15% or higher) using
the FORS only, and then the combined risk scores, and the
observed and predicted event rates compared in each cat-
egory (Supplementary Table 6). The FORS and combined
scores both accurately estimated the rates of diabetes in
each of the four categories of predicted risk. In addition, we
performed the Hosmer-Lemeshow goodness of ﬁt test,
which conﬁrmed that there was no signiﬁcant difference
between the observed and predicted risks for either the
FORS only (P = 0.65) or the combined score (P = 0.10)
(Supplementary Table 7 and Supplementary Fig. 4).
NRI and IDI
We next tested whether adding the genetic information to
the FORS more accurately predicted risk of T2D as
assessed by the NRI measure using these absolute risk
categories. An individual with incident T2D was consid-
ered to be correctly reclassiﬁed if they shifted to a higher
risk category when the genetic information was added,
while a shift to a lower risk score was regarded as
incorrect reclassiﬁcation, with the opposite being the
case for participants who remained free of T2D. The
addition of the gene score to the FORS resulted in an NRI
of 8.1% (95% CI 5.0–11.2; P = 3.3 3 1027) (Table 4A).
The addition of the gene score had less effect on the
reclassiﬁcation of those who remained T2D free. This is
illustrated in Fig. 4A and B, plotting the phenotypic score
against the combined phenotypic and genetic scores, us-
ing as an example the 15% risk category. For most indi-
viduals, there is a strong correlation between FORS and
the FORS plus gene score (green). In Fig. 4A, for those
who remained free of T2D, more individuals moved up
a risk category (blue) than down a risk category (red)
when the gene score was added to the phenotypic risk
score resulting in a negative net reclassiﬁcation. In those
who did develop T2D (Fig. 4B), addition of the gene score
to FORS also resulted in more individuals moving up
a risk category (blue), than down (red), leading to a posi-
tive net reclassiﬁcation. The percentage of individuals
with T2D moving up was substantially more than the
percentage of nondiabetic individuals moving up, result-
ing in a signiﬁcant positive NRI. For the continuous NRI
(18), which is independent of cut points, the improve-
ment was 29.7% (23.7–35.7; P = 2.04 3 10223) (Supple-
mentary Fig. 6), composed of an event NRI of 13% and
a nonevent NRI of 17%. This 30% improvement corre-
sponds to a small to medium Cohen effect size of 0.37
(18). The discrimination slope improved from 0.076 to
0.089, giving an IDI of 0.013 (0.009–0.017; P = 6.15 3
10211), and for IDI, the improvement was 0.013
(0.009–0.017; P = 6.15 3 10211) (Supplementary Fig. 7).
Table 2—Quintiles of FORS and externally weighted 65-gene score in the combined studies
Quintile FORS Externally weighted gene score
FORS and externally weighted
gene score
1 1.00 1.00 1.00
2 2.83 (1.93–4.15) 1.37 (1.05–1.79) 2.62 (1.76–3.92)
3 4.28 (2.97–6.17) 1.36 (1.04–1.78) 4.73 (3.23–6.92)
4 7.76 (5.39–11.16) 2.01 (1.56–2.58) 7.74 (5.32–11.27)
5 21.07 (14.86–29.88) 2.70 (2.12–3.43) 22.59 (15.75–32.41)
Per quintile 2.07 (1.94–2.21); P = 2.60 3 102106 1.28 (1.21–1.34); P = 9.03 3 10220 2.12 (1.99–2.27); P = 7.71 3 102111
Per SD 2.70 (2.48–2.93); P = 5.40 3 102121 1.43 (1.33–1.54); P = 2.25 3 10222 2.83 (2.61–3.08); P = 3.08 3 102132
Data are presented as OR (95% CI).
Table 3—AROC (95% CI) and the false-positive detection rates for the combined data
OR (95% CI)
top vs. bottom
quintile
AROC for combined
studies
(95% CI)
Detection rate for 5%
false positive
(95% CI)
Detection rate for 10%
false positive
(95% CI)
Externally weighted gene score 2.70 (2.12–3.43) 0.60 (0.58–0.62) 11.75% (9.54–13.95) 19.89% (17.14–22.63)
FORS 21.07 (14.86–29.88) 0.75 (0.73–0.77) 18.56% (15.9–21.22) 30.67% (27.51–33.82)
FORS + externally weighted gene
score 22.59 (15.75–32.41) 0.76 (0.75–0.78)* 23.14% (20.23–26.05) 37.28% (33.95–40.61)
*P = 0.003. P value derived from the comparison with FORS alone.
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Stratiﬁcation by BMI, Age, and Sex
To examine the inﬂuence of BMI and age on the ability of
the genetic score to improve incident case discrimination,
we conducted a prespeciﬁed analysis by tertiles of BMI
and age, and in men and women separately. For BMI
tertiles (,24.5, 24.5–27.5, and.27.5 kg/m2), the calibra-
tion of the combined score is presented in Supplementary
Fig. 8. Risk tended to be overestimated for those in the
bottom tertile (P = 0.0009) and underestimated for those
in the middle and top tertiles (P = 0.02 and P = 9.76 3
1027, respectively). The NRI is presented in Table 4B–D.
In those who had a BMI ,24.5 kg/m2, the NRI was 27.6%
(95% CI 17.7–37.5; P = 4.82 3 1028). For those in the
middle tertile (24.5–27.5 kg/m2), the NRI was still statisti-
cally signiﬁcant (11.6% [95% CI 5.8–17.4]; P = 9.8831025).
By contrast, thosewith aBMI above 27.5 kg/m2had anNRI of
2.6% (95%CI21.4 to 6.6;P=0.20). Adding the gene score to
the FORS after stratiﬁcation improved the AROC by 0.037
Figure 1—Forest plot showing the 10% detection rate for all seven studies for (A) the Framingham phenotypic score alone and (B)
Framingham T2D score plus the externally weighted gene score. DR10, 10% detection rate.
Figure 2—The distribution of the 65-SNP gene score, weighted by the external published b-values in the combined studies. Superimposed
are the log ORs for T2D.
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(95% CI 0.018–0.056; P = 0.0001) for those in the lowest
tertile of weight but not for those in the middle tertile
(0.017 [0.004–0.031]; P = 0.01) or the top tertile (0.013
[95% CI 0.002–0.023]; P = 0.02; P = 0.03 for difference
between BMI categories) (Supplementary Table 8). Little
difference was seen in model performance for different
age categories (see Supplementary Fig. 9 and Supplementary
Table 9) or by sex (Supplementary Fig. 10 and Supplemen-
tary Table 10). However, while the NRI was signiﬁcant
in men, it reached borderline statistical signiﬁcance in the
women, which might reﬂect the reduced power in the women,
since there were far fewer women in the study (men, 554
with T2D, 7,784 T2D free; women, 250 with T2D, 4,706
T2D free) (Supplementary Table 11).
DISCUSSION
In this study, we have examined the predictive ability of 65
T2D risk variants in predicting T2D risk in the largest
number of incident T2D patients reported to date. This
included pooled information from multiple prospective
cohort studies with over 13,000 individuals with relevant
phenotypic data prior to the onset of disease. We used
a range of metrics in our analysis: discrimination as assessed
by the AROC, the strength of the association as determined
by the OR and quintiles of risk, risk detection at 5% and 10%
FPRs, and reclassiﬁcation based on the NRI index. We also
examined whether adding genotypic scores to an established
phenotypic risk prediction tool changes prediction differ-
ently within prespeciﬁed subgroups. This was true for BMI
but, contrary to expectation, not for age stratiﬁcation.
In the prospective analysis of 804 incident cases
compared with 12,490 T2D free, the FORS performed
reasonably well, with an AROC of 0.75 for the seven com-
bined studies, compared with an AROC of 0.85 in the
Framingham Offspring Study itself (5), providing external
validation for the algorithm. The overall OR for develop-
ing T2D was 21.1 in the top quintile versus the bottom
quintile for score. The addition of a 65-SNP gene score to
the FORS improved the correct classiﬁcation of individu-
als with T2D into higher risk categories by 6.2%. When
the gene score was added to the FORS score, there was
a small, but signiﬁcant, improvement in the AROC. For
individuals with a BMI of 25 kg/m2 or below, this im-
provement was even greater. Examining this BMI effect
using repeat BMI measures may be as good, if not better,
than a genetic score that is ﬁxed in time. Examination of
the BMI changes over time and replication in a larger
cohort is required to validate these results.
For a gene score to be effective, it should improve the
reclassiﬁcation of individuals with T2D into a more
accurate risk category over and above the phenotypic
risk score. The 65 SNP–weighted gene score did this. In
actual terms, at a 10% FPR, the combined phenotypic and
genetic risk score led to the correct identiﬁcation of an
additional 53 (6.6%) of the 804 cases. We examined
whether genetics would play a bigger role in T2D risk in
the absence of the environmental challenge of obesity.
With stratiﬁcation by BMI, individuals in the lowest ter-
tile of BMI (,24.5 kg/m2) had an NRI of 27.6% compared
with those in the top tertile, with an NRI of 2.6%, con-
ﬁrming our hypothesis.
We previously examined the WHII (6) (n = 5,535) and
reported that the FORS (5) performed better than the
Cambridge T2D score (20), which incorporates only the
Figure 3—The receiver operating curve for the seven combined studies.
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Table 4—NRI based on addition of gene score to FORS, calculated using risk cutoffs of 5, 10, and 15% for 10-year risk
Predicted risk FORS
Number of people Reclassiﬁed Net correctly
reclassiﬁed#5 5–9.9 10–14.9 $15 Increased risk Decreased risk
A. For the whole cohort
Plus externally weighted gene score:
no diabetes (n 5 18,715.81) 1,782.23 2,138.63 1.9% (1.2–32.6)
,5 10,406.62 582.00 36.28 0
5–9.9 1,064.52 1,967.29 542.56 118.24
10–14.9 35.16 647.23 682.39 503.15
$15 6.55 78.89 306.28 1,738.65
Plus externally weighted gene score:
incident diabetes (n 5 1,121.86) 185.96 116.49 6.2% (3.2–9.2)
,5 279.01 34.13 1 0
5–9.9 36.80 81.20 55.97 15.82
10–14.9 0 45.93 71.24 79.04
$15 0 11.73 22.03 387.96
B. BMI tertile 1 (BMI ,24.5)
Plus externally weighted gene score:
no diabetes (n 5 6,267.82) 448.8 616.52 2.7% (1.7–3.7)
,5 4,202.14 95.95 2 0
5–9.9 540.06 834.1 232.65 63.3
10–14.9 1 35.27 36.08 54.9
$15 0 7.13 33.06 130.18
Plus externally weighted gene score:
incident diabetes (n 5 147.53) 45.88 9.13 24.9% (15.0–34.8)
,5 56 3 0 0
5–9.9 6.13 21.06 26.32 7.82
10–14.9 0 3 2.21 8.74
$15 0 0 0 13.25
C. BMI tertile 2 (BMI 24.5–27.4)
Plus externally weighted gene score:
no diabetes (n 5 6,526.66) 706.02 715.15 0.1% (21.0 to 1.3)
,5 3,684.61 267.53 22.95 0
5–9.9 339.91 675.31 185.82 34.24
10–14.9 20.83 253.93 266.22 195.48
$15 6.55 22.56 71.37 479.35
Plus externally weighted gene score:
incident diabetes (n 5 308.31) 58.26 22.93 11.5% (5.7–17.2)
,5 112.17 17.13 0 0
5–9.9 7.13 23.63 12.25 6
10–14.9 0 11.66 18.64 22.88
$15 0 1 3.14 72.68
D. BMI tertile 3 (BMI $27.5)
Plus externally weighted gene score:
no diabetes (n 5 5,921.35) 627.42 806.96 3.0% (1.8–4.3)
,5 2,519.87 218.52 11.33 0
5–9.9 184.55 457.88 124.09 20.71
10–14.9 13.33 358.03 380.1 252.77
$15 0 49.2 201.85 1,129.12
Plus externally weighted gene score:
incident diabetes (n 5 666.02) 81.82 84.43 20.4% (24.2 to 3.4)
,5 110.83 14 1 0
5–9.9 23.55 36.52 17.4 2
10–14.9 0 31.26 50.39 47.42
$15 0 10.73 18.89 302.03
A. Values are weighted to take into account sampling design, thus accounting for the fact that the number of individuals is not an integer.
P value for heterogeneity5 0.002. I25 71.1%. NRI (95%CI)5 8.1% (5.0–11.2), no adjustment for study; P5 3.313 1027. NRI (95% CI)5
6.6% (3.6–9.7), results frommeta-analysis of individual study results (ﬁxed effects); P5 2.03 1025. NRI (95% CI)5 7.7% (1.7–13.8), results
frommeta-analysis of individual study results (random effects); P5 0.01. B. NRI (95%CI)5 27.6% (17.7–37.5); P5 4.823 10–8.C. NRI (95%
CI) 5 11.6% (5.8–17.4); P 5 9.88 3 10–5. D. Values are weighted to take into account sampling design, thus accounting for the fact that the
number of individuals is not an integer. NRI (95% CI) 5 2.6% (21.4 to 6.6); P 5 0.20.
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routinely assessed variables, and that a 20-SNP gene score
did not improve prediction when added to the FORS, with
the AROC remaining at 0.78. When repeating analysis on
all seven studies reported here, discrimination was not
signiﬁcantly improved (difference in AROC 0.005 [95%
CI 0.003–0.013]; P = 0.23), while the NRI for those
same 20 SNPs was 5.9% (95% CI 2.3–9.5) (see Supple-
mentary Table 12), which did not differ signiﬁcantly from
the 8.1% NRI found for the 65 SNPs (P = 0.36).
The 20 SNPs were primarily in genes encoding proteins
involved in pancreatic b-cell function (6). The extended
65 variants in the present analysis, however, involve ad-
ditional pathways, including adipocytokine signaling, cell
cycle regulation, and CREBBP-related transcription (8),
thus widening the implicated processes leading to T2D.
Simulation analysis of GWAS identiﬁed additional SNPs
associated with T2D susceptibility (8), but with decreasing
effect sizes, their impact on risk prediction is likely to be
very small. This explains why with ;60, T2D gene score
prediction has reached a plateau (21), based on the 62-
SNP gene score analysis (11). Of interest, in the search for
rare T2D variants of large effect, while exome sequencing
has failed to identify these in the case-control setting (22)
within a T2D family, exome sequencing has identiﬁed
a rare cSNP in the gene encoding early endosome anti-
gen 1 (EEA1) (23).
Recent assessment of risk scores pooled across studies
have highlighted the potential pitfalls, in particular, when
assessing the incremental value of adding novel predictors
to established predictors (24). These include variations in
Figure 4—Scatter plot showing the correlation between Framingham T2D score and Framingham T2D score plus the externally weighted
gene score. A: Those who remained T2D free. B: Incident T2D cases.
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distributions of the novel predictors and the variation in
impact of these new predictors between studies. Gene dis-
tributions are unlikely to vary between the studies presented
here, all of which are almost exclusively of white European
participants, and there is little reason to suspect their im-
pact would vary between studies. Concerning the overall NRI
statistic, the inverse weighting approach we have used to
pool across studies may give more weight to studies with
few events and bias results toward the null. Accordingly, we
have presented event NRI and nonevent NRI both for anal-
ysis of all participants and for subgroups.
There are, however, several limitations to our study.
Any single genetic risk marker is limited by effect size,
overcome to some extent by using them in combination in
a gene score. Better diagnosis of the subtypes of T2D, e.g.,
in lean individuals, is likely to make risk prediction more
precise. To conﬁrm the generalizability of our ﬁndings,
replication in an independent set of cohort studies is
needed. One major problem in developing a clinically
useful SNP gene score is the underlying genetic architec-
ture of T2D. While individuals carrying many risk alleles
are at a much higher risk of T2D than those carrying
fewer alleles, they represent only a small proportion of
the population. The consequence of this is that individ-
uals with an intermediate number of risk alleles will
account for the majority of cases of T2D because of the
large number of people at intermediate risk in the
population (see Fig. 2). Because of this, there is a substan-
tial overlap of the distribution of risk alleles among indi-
viduals who develop diabetes and those who remained
disease free; thus it is difﬁcult to set a cut point of a
gene score that reliably discriminates T2D cases. Fifty-three
out of the 65 SNPs used in this study had effect sizes in
concordance with those published in meta-analysis (17).
We used these external weights from published meta-
analyses of .100,000 subjects (8) to minimize the sam-
pling errors and to avoid overﬁtting the genetic risk.
The previous reports using risk scores of 40–62 SNPs,
from de Miguel-Yanes et al. (9), Walford et al. (10), and
Vassy et al. (11), have to be considered in the context that
they all performed their analysis in the setting of the
same study, the Framingham Offspring Study, and fur-
thermore, the phenotypic risk score was derived from the
same Framingham Offspring Study. When applied to the
Framingham Offspring Study itself, the phenotypic risk
score provides a better C-statistic or equivalent AROC
(0.85) (5) than in the combined studies presented here
(0.75). This is not surprising, as the phenotypic risk score
always performs better in the study in which it originated.
Our study ﬁndings, although conﬁrmatory, take this anal-
ysis forward in that we examined the predictive impact of
65 SNPs in a cohort of almost double the number of in-
cident cases and in a data set that was independent of the
Framingham Offspring Study, thus validating the pheno-
typic risk score.
In conclusion, an increase in the number of genetic risk
variants for T2D to 65 risk SNPs slightly improved
discrimination and classiﬁcation of individuals with the
disease into a higher risk category, thus demonstrating
incremental value for prediction. Although these results
require further independent validation and any suggestion
of including genetic variants in risk prediction tools would
need to be assessed for clinical and cost-effectiveness in
randomized controlled trials, our ﬁndings suggest that
there is potential for common variants of small effect in
combination to aid in risk prediction for T2D. Unlike
statins used prophylactically in coronary disease heart
prevention, metformin is not used in the same way to
prevent T2D. Although it is hoped that those with a high
T2D genetic risk might be especially motivated to make
lifestyle changes, this has not always proved to be so (25).
Genetic variants need to be measured only once for each
person, and most primary health care practitioners in high-
income countries make use of electronic records. Thus
taking into account the genetic component (if this is
recorded, once obtained) should be feasible.
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